Navigation Links
Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
Date:10/6/2008

e of food intake and metabolism. We believe that Contrave is possibly the first treatment for obesity to address a second site, the reward system in the brain that controls food preference and food cravings. In clinical trials, Contrave has initiated and sustained significant weight loss over one year of treatment (approximately 8.0% - 10.7% in patients completing 48 weeks of therapy) by reducing appetite, increasing metabolism [0]and allowing the body to continue losing weight by offsetting its natural tendency to fight back and slow down the weight loss process. We expect to receive data from the first of our Contrave Phase 3 trials in January of 2009 and the remaining three trials by mid next year.

About Empatic(TM)

Empatic is a fixed dose combination of bupropion SR with our proprietary sustained release formulation of zonisamide. Research indicates that zonisamide inhibits AgRP, a system associated with increasing appetite while bupropion increases metabolism. Based on the strength of these results and the unique Empatic mechanism of action, the Company selected this product combination to complement our Contrave clinical development program.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing, execution and completion of clinical trials of its product candidates, the timing of an NDA submission for Contrave, the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave and Empatic, and the potential for nal
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015 Fair Rate Funding, ... Jersey , reports a dramatic increase in lawsuit filings ... of filed Xarelto lawsuits in the Philadelphia ... to over 300 cases.  In the Louisiana ... for the Eastern District of Louisiana , ...
(Date:9/4/2015)... 2015  Pharmaceutical companies today rely heavily on ... Specialists (FBMS) to build and strengthen vital relationships ... in critical therapeutic areas. To ... are expanding the critical MSL function into global ... objectives and to achieve regional consistency, compliance, and ...
(Date:9/4/2015)... , Sept. 4, 2015  Dohmen Company CEO ... the Metropolitan Milwaukee Association of Commerce,s annual ,Future 50, ... the Pfister Hotel. The ,Future 50, Awards highlights the ... and young firms headquartered in the seven-county ... called Milwaukee home for more ...
Breaking Medicine Technology:Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2Dohmen CEO Cynthia LaConte to Keynote MMAC 'Future 50' Awards Luncheon 2
... ... 7 , Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ) and ... of positive data from a phase 1 study of TRU-016 in ... 2009 American Society of Hematology (ASH) Annual Meeting. TRU-016 is a ...
... , HOBOKEN, N.J., Dec. 7 ... the U.S. Food and Drug Administration has approved ... in patients with all types of von Willebrand disease (VWD). Wilate® ... Factor VIII Concentrate (Human) that demonstrated efficacy for all types of ...
Cached Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5
(Date:9/4/2015)... ... September 04, 2015 , ... ... communities, is launching a charity effort to provide for the family of Grace, ... an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – the inability ...
(Date:9/4/2015)... ... 2015 , ... Inmar announced today that its regulatory experts ... Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , With the complex ... industry, it can be difficult for companies to navigate, stay abreast of all ...
(Date:9/4/2015)... Texas (PRWEB) , ... September 04, 2015 , ... ... recipient of three separate “Partner of the Year” awards at this year’s Microsoft ... being named Microsoft’s 2015 “Partner of the Year” Award Winner for Data Platform ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... technology is now available at CitiDent. CEREC is a newer method for creating ... saving time for patients by eliminating the need for multiple appointments, CEREC produces ...
(Date:9/4/2015)... ... September 04, 2015 , ... Mike Day, a former Navy SEAL who ... the Ironman World Championships in Kona on October 10th. , Mike is running the ... (TBI) through combat and the cutting-edge treatments that restore their quality of life. ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2
... included nearly 57,000 women who had been followed for ... -- Hormone therapy may lower a woman,s risk of ... the hormones. , This new finding, published in the ... , further complicates an already murky picture of the ...
... SANTA CLARA, Calif., January 8 Align Technology,Inc. (Nasdaq: ... today that the,Company will report fourth quarter and fiscal ... the close of market. Financial results will,be released over ... on the,Investor Relations section of the Company,s website at, ...
... Calif., Jan. 8 TEAC America, Inc. launches its,next ... dye-sublimation disc printer available, during the CES Show at,the ... The P-55C printer can be integrated ... Discathlon 2. With TEAC,s,AL220S and AL550S, customers can ...
... Vyvanse as the Clinical Gold Standard, According to ... 8 Decision Resources, one of the world,s ... and healthcare issues, finds that physicians indicate there ... effective nonstimulant therapy approved for adult attention-deficit/hyperactivity disorder ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today ... officer. Formerly president and chief operating officer,Popovits is ... In addition, G.,Bradley Cole has been appointed as chief ... chief financial officer, reporting to Popovits. , ...
... and FirstDoc (Documentum) Solutions Deliver Regulatory Document Management ... CSC (NYSE: CSC ) announced today ... content management (ECM) solutions, adding features designed to ... the document life cycle and the growing collaboration ...
Cached Medicine News:Health News:Hormone Therapy May Cut Colorectal Cancer Risk 2Health News:Align Technology to Announce Fourth Quarter and Fiscal Year 2008 Results on January 28, 2009 2Health News:TEAC America Launches its Next Generation P-55C Printer, World's Fastest Dye-Sublimation Disc Printer 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 2Health News:Physicians Express Continued Need for Safe and Effective Nonstimulant Therapies in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder 3Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 2Health News:CSC Announces New Releases of Enterprise Content Management Solutions for Life Sciences Industry 3
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
... Shaker provides the exact agitation needed ... very slow to fast speed and ... a gentle wave motion that lifts ... membranes to achieve faster, more uniform ...
Conversion Kits For Modular Incubator Chamber...
Medicine Products: